|
Acumen Physician Solutions Products to Interface with DSI Renal - Yahoo Finance UK |
 |
 |
|
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Acumen Physician Solutions will join with DSI Renal to interface with DSI’s proprietary electronic medical records. In turn, DSI, the third-largest dialysis services company, will recommend using Acumen software in its dialysis units.
DSI’s relationship with Acumen reinforces the companies’ joint commitment to physicians. DSI and Acumen worked together to upgrade their respective systems to allow physician rounding notes from Acumen to flow seamlessly into DSI’s clinical system (PEARL), eliminating double entry and ensuring compliance.
“This partnership will provide increased visibility within the U.S. health care industry for both Acumen and DSI Renal,” said Acumen president Dana Hensley. “Acumen’s biotechnology has been used in nephrology practices nationwide, and we’re ready to partner with a large dialysis services company.”
DSI Renal will recommend using Acumen’s electronic health records (EHR) system as well as Mobile Charge Capture, a mobile application that works within a nephrology practice management system to streamline the patient-to-doctor communication process. Mobile Charge Capture is designed to minimize error and promote accuracy within EHR systems. It can be used in the dialysis center, lab or hospital, and is compatible with an iPad, iPhone or PC.
“Physicians’ patients and caseloads are increasing every day, so anything their partners and vendors can do to reduce the administrative burden allows physicians to spend more time with patients and increases the efficiency of the overall health care system,” said DSI Renal executive vice president Judy Lefkovitz. “These time-saving, requested enhancements show the commitment that DSI and Acumen have to their physician partners.”
About Acumen Physician Solutions
Acumen Physician Solutions was formed to develop and deliver intuitive software tools to assist nephrologists in the practice of medicine. The Acumen solution was designed by nephrologists and made available under an Internet-based service model. Our products include: Acumen Practice Management, Acumen Plus, Acumen Mobile Charge Capture, Acumen nEHR and Acumen PQRS. Acumen Physician Solutions, based in Franklin, Tenn., is a wholly owned subsidiary of Fresenius Medical Care North America. More information regarding Acumen Physician Solutions and Acumen Nephrology can be found at www.AcumenMD.com.
About DSI Renal
DSI Renal (formed as Dialysis Newco, Inc.) is a leading provider of dialysis services in the United States, offering state-of-the-art treatment for patients suffering from chronic kidney failure and renal disease. Together with its physician partners, DSI Renal owns and operates 92 dialysis clinics in 22 states. The company plans for growth through acquisition and development of new clinics as well as through establishment of additional joint venture partnerships with leading nephrologists for the clinic, hospital and alternative settings. For more information, please visit www.dsi-corp.com.
<![CDATA[.bwalignc {text-align: center !important;} ;} ]]>
|
|
Acumen Physician Solutions Products to Interface with DSI Renal - Business Wire (press release) |
|
|
|
NASHVILLE, Tenn.--(BUSINESS WIRE)--Acumen Physician Solutions will join with DSI Renal to interface with DSI’s proprietary electronic medical records. In turn, DSI, the third-largest dialysis services company, will recommend using Acumen software in its dialysis units.
DSI’s relationship with Acumen reinforces the companies’ joint commitment to physicians. DSI and Acumen worked together to upgrade their respective systems to allow physician rounding notes from Acumen to flow seamlessly into DSI’s clinical system (PEARL), eliminating double entry and ensuring compliance.
“This partnership will provide increased visibility within the U.S. health care industry for both Acumen and DSI Renal,” said Acumen president Dana Hensley. “Acumen’s biotechnology has been used in nephrology practices nationwide, and we’re ready to partner with a large dialysis services company.”
DSI Renal will recommend using Acumen’s electronic health records (EHR) system as well as Mobile Charge Capture, a mobile application that works within a nephrology practice management system to streamline the patient-to-doctor communication process. Mobile Charge Capture is designed to minimize error and promote accuracy within EHR systems. It can be used in the dialysis center, lab or hospital, and is compatible with an iPad, iPhone or PC.
“Physicians’ patients and caseloads are increasing every day, so anything their partners and vendors can do to reduce the administrative burden allows physicians to spend more time with patients and increases the efficiency of the overall health care system,” said DSI Renal executive vice president Judy Lefkovitz. “These time-saving, requested enhancements show the commitment that DSI and Acumen have to their physician partners.”
About Acumen Physician Solutions
Acumen Physician Solutions was formed to develop and deliver intuitive software tools to assist nephrologists in the practice of medicine. The Acumen solution was designed by nephrologists and made available under an Internet-based service model. Our products include: Acumen Practice Management, Acumen Plus, Acumen Mobile Charge Capture, Acumen nEHR and Acumen PQRS. Acumen Physician Solutions, based in Franklin, Tenn., is a wholly owned subsidiary of Fresenius Medical Care North America. More information regarding Acumen Physician Solutions and Acumen Nephrology can be found at www.AcumenMD.com.
About DSI Renal
DSI Renal (formed as Dialysis Newco, Inc.) is a leading provider of dialysis services in the United States, offering state-of-the-art treatment for patients suffering from chronic kidney failure and renal disease. Together with its physician partners, DSI Renal owns and operates 92 dialysis clinics in 22 states. The company plans for growth through acquisition and development of new clinics as well as through establishment of additional joint venture partnerships with leading nephrologists for the clinic, hospital and alternative settings. For more information, please visit www.dsi-corp.com.
|
|
|
PPIs, Low Magnesium Linked in Renal Transplant Patients - Renal and Urology News |
|
|
May 04, 2015
Study of renal transplant patients also shows that proton pump inhibitors are associated with increased arterial stiffness.
PHILADELPHIA—Proton pump inhibitor (PPI) use is associated with decreased magnesium absorption and increased arterial stiffness in renal transplant recipients, according to a new study presented at the 2015 American Transplant Congress.
Siren Sezer, MD, and colleagues at the Baskent University in Ankara, Turkey, retrospectively studied 354 renal transplant recipients with a mean age of 38.6 years and stable graft function. All had received their transplant at least 36 months previously. The researchers divided subjects into 3 groups: PPI users (164 patients); H2 receptor blocker users (96 patients); and a control group not taking any stomach-protecting agents (94 patients).
The PPI group had a significantly lower mean serum magnesium level compared with the H2 receptor block group and control group (1.5 vs. 1.7 and 1.7 mg/dL).
The researchers measured pulse wave velocity (PWv) to assess arterial stiffness. PWv values were significantly higher in the PPI group than the H2 receptor block group and control group (7.3 vs. 6.3 and 6.2 cm/sec, respectively).
|
|
Variable Patient Responses to Catheter-Based Renal Denervation Therapy is ... - Yahoo Finance UK |
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--
CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today that its scientists have published data and analyses (“Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension”) that provide critical insights into the predictability, variability and treatment success of catheter-based renal denervation (RDN) therapy. These data suggest that new, optimal alternative devices compared to first-generation RDN systems may enhance or assure efficacy and are published in the FOCUS article in the latest issue of Science Translational Medicine, a publication of the American Association for the Advancement of Science (AAAS).
Click here for CBSET Press Kit
“Though a large body of scientific research has convincingly demonstrated the link between sympathetic activity and hypertension, catheter-based renal denervation has been confounded by unreliable efficacy in some late-stage clinical trials. The published data have demonstrated that anatomical asymmetries along the length and circumference of the renal artery can limit the efficacy of ablation therapies in the treatment of resistant hypertension. These data increase our insight into the connection between target anatomy and patient efficacy post-renal denervation by single and multiple RF electrode catheters,” said Dr. Felix Mahfoud, M.D.,Department of Internal Medicine III, Saarland University, Homburg/Saar, Germany, co-author and EuroPCR co-course director.
“Conflicting data from recent clinical trials must not deter the community. Sympathetic denervation and neuromodulation techniques still provide an exciting opportunity for the treatment of diseases with increased sympathetic tone, such as hypertension and of a variety of other cardiovascular diseases. The current device therapies are still in their infancy, and the rate of technological advancement in this field is accelerating exponentially. These preclinical data help explain the prior clinical variability documented following renal denervation in humans and illustrate that electrode irrigation can protect the artery wall during efficacious ablations without diminishing ablation area in the nerve rich peri-arterial compartment,” said computational modeling expert and CBSET Principal Scientist Dr. Rami Tzafriri, lead author of the published study.
“Mechanistic insight bridges the preclinical and clinical experiences and is in the end the only effective means of resolving seeming conflicts or disparities in observations. CBSET’s groundbreaking work in renal denervation has provided the precision needed to produce a coherent paradigm by which to appreciate this complex field. The systematic integration of quantitative computational-modeling with rigorous preclinical evaluation has now created a framework by which to optimize the potential of sympathetic denervation and modulation as a treatment modality,” added Elazer Edelman, M.D., Ph.D., chairman and co-founder of CBSET, and senior author on the paper.
For a copy of the paper, or to learn more about CBSET, please contact: Dr. Erica Smith, Director, Business Development: +1-781-296-5319,
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
About CBSET
CBSET Inc., 500 Shire Way, Lexington, MA 02421 — is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, combination medical device and drug-eluting products. CBSET occupies a 35,000-square-foot, state-of-the-art facility near Boston that includes a vivarium, catheterization/imaging labs, surgical suites, dedicated labs for SEM, histopathology/pathology, and drug metabolism and pharmacokinetics. CBSET offers the latest equipment for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS, optical coherence tomography (OCT), endoscopy/laparoscopy, surgical video recording, histology, microradiography, and SEM (Scanning Electron Microscopy).
<![CDATA[.bwalignc {text-align: center !important;} ;} ]]>
Contact: Ronald Trahan Associates Inc.
Ronald Trahan, +1-508-359-4005, x108
APR, President
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
